# AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) approved for both neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer.

*biotech · news · 2026-05-26 · Medical Xpress*

## Key points

- FDA approved AstraZeneca's Enhertu for neoadjuvant and adjuvant treatment of HER2-positive early breast cancer.
- In DESTINY-Breast11, Enhertu followed by THP yielded a 67.3% pathologic complete response versus 56.3% with standard care.
- DESTINY-Breast05 results showed Enhertu reduced risk of invasive recurrence or death by 53% versus T-DM1.
- At three years, 92.4% of Enhertu-treated patients were disease-free compared to 83.7% for T-DM1.

**Companies:** AstraZeneca
**Countries:** United States

[Read the full story on Medical Xpress](https://medicalxpress.com/news/2026-05-fda-enhertu-neoadjuvant-adjuvant-treatment.html)

---

Canonical: https://newsio.io/n/3e27ac30-6a8c-42e9-b3a3-7e83c70725aa/astrazenecas-enhertu-fam-trastuzumab-deruxtecan-nxki-approved-for-both-neoadjuva
Summarized by Newsio from Medical Xpress. https://newsio.io/how-it-works